Terms: = Skin cancer AND PAX3, MGC120382, 5077, ENSG00000135903, CDHS, MGC120383, HUP2, P23760, WS1, MGC120384, MGC134778, MGC120381 AND Treatment
23 results:
1. Melanocyte progenitor cells reside in human subcutaneous adipose tissue.
Ikeda Y; Wada A; Hasegawa T; Yokota M; Koike M; Ikeda S
PLoS One; 2021; 16(8):e0256622. PubMed ID: 34432824
[TBL] [Abstract] [Full Text] [Related]
2. Activated Beta-Catenin Signaling Ameliorates Radiation-Induced skin Injury by Suppressing Marvel D3 Expression.
Cao J; Zhong L; Feng Y; Qian K; Xiao Y; Wang G; Tu W; Yue L; Zhang Q; Yang H; Jiao Y; Zhu W; Cao J
Radiat Res; 2021 Feb; 195(2):173-190. PubMed ID: 33045079
[TBL] [Abstract] [Full Text] [Related]
3. Primary cutaneous alveolar rhabdomyosarcoma in an adolescent - A challenging diagnosis.
Calvão J; Cardoso JC; Ramos L; Figueiredo A
Pediatr Dermatol; 2020 Jan; 37(1):184-186. PubMed ID: 31797424
[TBL] [Abstract] [Full Text] [Related]
4. Health risk assessment of trihalomethanes in water treatment plants in Jiangsu Province, China.
Wang Y; Zhu G; Engel B
Ecotoxicol Environ Saf; 2019 Apr; 170():346-354. PubMed ID: 30544095
[TBL] [Abstract] [Full Text] [Related]
5. UV-Radiation Response Proteins Reveal Undifferentiated Cutaneous Interfollicular Melanocytes with Hyperradiosensitivity to Differentiation at 0.05 Gy Radiotherapy Dose Fractions.
Fessé P; Qvarnström F; Nyman J; Hermansson I; Ahlgren J; Turesson I
Radiat Res; 2019 Jan; 191(1):93-106. PubMed ID: 30407899
[TBL] [Abstract] [Full Text] [Related]
6. A pax3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITF
Smith MP; Rana S; Ferguson J; Rowling EJ; Flaherty KT; Wargo JA; Marais R; Wellbrock C
Pigment Cell Melanoma Res; 2019 Mar; 32(2):280-291. PubMed ID: 30277012
[TBL] [Abstract] [Full Text] [Related]
7. Upregulation of
Villareal MO; Kume S; Neffati M; Isoda H
Biomed Res Int; 2017; 2017():8303671. PubMed ID: 29359158
[TBL] [Abstract] [Full Text] [Related]
8. Autophagy-dependent crosstalk between GILT and PAX-3 influences radiation sensitivity of human melanoma cells.
Hathaway-Schrader JD; Doonan BP; Hossain A; Radwan FFY; Zhang L; Haque A
J Cell Biochem; 2018 Feb; 119(2):2212-2221. PubMed ID: 28857256
[TBL] [Abstract] [Full Text] [Related]
9. Targeting melanocyte and melanoma stem cells by 8-hydroxy-2-dipropylaminotetralin.
Bonchak JG; Eby JM; Willenborg KA; Chrobak D; Henning SW; Krzywiec A; Johnson SL; Le Poole IC
Arch Biochem Biophys; 2014 Dec; 563():71-8. PubMed ID: 25132642
[TBL] [Abstract] [Full Text] [Related]
10. Rapidly progressive congenital rhabdomyosarcoma presenting with multiple cutaneous lesions: an uncommon diagnosis and a therapeutic challenge.
Rekhi B; Qureshi SS; Narula G; Gujral S; Kurkure P
Pathol Res Pract; 2014 May; 210(5):328-33. PubMed ID: 24635971
[TBL] [Abstract] [Full Text] [Related]
11. Circulating tumor cells as prognostic biomarkers in cutaneous melanoma patients.
Kiyohara E; Hata K; Lam S; Hoon DS
Methods Mol Biol; 2014; 1102():513-22. PubMed ID: 24258996
[TBL] [Abstract] [Full Text] [Related]
12. A STATement on vemurafenib-resistant melanoma.
Hartsough EJ; Aplin AE
J Invest Dermatol; 2013 Aug; 133(8):1928-9. PubMed ID: 23856932
[TBL] [Abstract] [Full Text] [Related]
13. Stat3-targeted therapies overcome the acquired resistance to vemurafenib in melanomas.
Liu F; Cao J; Wu J; Sullivan K; Shen J; Ryu B; Xu Z; Wei W; Cui R
J Invest Dermatol; 2013 Aug; 133(8):2041-9. PubMed ID: 23344460
[TBL] [Abstract] [Full Text] [Related]
14. Assessment of prognostic circulating tumor cells in a phase III trial of adjuvant immunotherapy after complete resection of stage IV melanoma.
Hoshimoto S; Faries MB; Morton DL; Shingai T; Kuo C; Wang HJ; Elashoff R; Mozzillo N; Kelley MC; Thompson JF; Lee JE; Hoon DS
Ann Surg; 2012 Feb; 255(2):357-62. PubMed ID: 22202581
[TBL] [Abstract] [Full Text] [Related]
15. Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma.
Koyanagi K; O'Day SJ; Boasberg P; Atkins MB; Wang HJ; Gonzalez R; Lewis K; Thompson JA; Anderson CM; Lutzky J; Amatruda TT; Hersh E; Richards J; Weber JS; Hoon DS
Clin Cancer Res; 2010 Apr; 16(8):2402-8. PubMed ID: 20371696
[TBL] [Abstract] [Full Text] [Related]
16. Wnt5A regulates expression of tumor-associated antigens in melanoma via changes in signal transducers and activators of transcription 3 phosphorylation.
Dissanayake SK; Olkhanud PB; O'Connell MP; Carter A; French AD; Camilli TC; Emeche CD; Hewitt KJ; Rosenthal DT; Leotlela PD; Wade MS; Yang SW; Brant L; Nickoloff BJ; Messina JL; Biragyn A; Hoek KS; Taub DD; Longo DL; Sondak VK; Hewitt SM; Weeraratna AT
Cancer Res; 2008 Dec; 68(24):10205-14. PubMed ID: 19074888
[TBL] [Abstract] [Full Text] [Related]
17. A phase II clinical trial of sorafenib in androgen-independent prostate cancer.
Dahut WL; Scripture C; Posadas E; Jain L; Gulley JL; Arlen PM; Wright JJ; Yu Y; Cao L; Steinberg SM; Aragon-Ching JB; Venitz J; Jones E; Chen CC; Figg WD
Clin Cancer Res; 2008 Jan; 14(1):209-14. PubMed ID: 18172272
[TBL] [Abstract] [Full Text] [Related]
18. [Transcription factors in the development and progression of melanoma].
Lesiak K; Sztiller-Sikorska M; Czyz M
Postepy Hig Med Dosw (Online); 2007 Oct; 61():576-95. PubMed ID: 17971761
[TBL] [Abstract] [Full Text] [Related]
19. Comprehensive expression profiling of tumor cell lines identifies molecular signatures of melanoma progression.
Ryu B; Kim DS; Deluca AM; Alani RM
PLoS One; 2007 Jul; 2(7):e594. PubMed ID: 17611626
[TBL] [Abstract] [Full Text] [Related]
20. Transfection of melanoma cells with antisense pax3 oligonucleotides additively complements cisplatin-induced cytotoxicity.
He SJ; Stevens G; Braithwaite AW; Eccles MR
Mol Cancer Ther; 2005 Jun; 4(6):996-1003. PubMed ID: 15956257
[TBL] [Abstract] [Full Text] [Related]
[Next]
